|
1
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Altieri DC: The molecular basis and
potential role of survivin in cancer diagnosis and therapy. Trends
Mol Med. 7:542–547. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gąsowska-Bodnar A, Bodnar L, Dąbek A,
Cichowicz M, Jerzak M, Cierniak S, Kozłowski W and Baranowski W:
Survivin expression as a prognostic factor in patients with
epithelial ovarian cancer or primary peritoneal cancer treated with
neoadjuvant chemotherapy. Int J Gynecol Cancer. 24:687–696. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu JL, Gao W, Kang QM, Zhang XJ and Yang
SG: Prognostic value of survivin in patients with gastric cancer: A
systematic review with meta-analysis. PLoS One. 8:e719302013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Deveraux QL and Reed JC: IAP family
proteins - suppressors of apoptosis. Genes Dev. 13:239–252. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kanwar JR, Shen WP, Kanwar RK, Berg RW and
Krissansen GW: Effects of survivin antagonists on growth of
established tumors and B7-1 immunogene therapy. J Natl Cancer Inst.
93:1541–1552. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pennati M, Colella G, Folini M, Citti L,
Daidone MG and Zaffaroni N: Ribozyme-mediated attenuation of
survivin expression sensitizes human melanoma cells to
cisplatin-induced apoptosis. J Clin Invest. 109:285–286. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang G, Li J, Zeng Z and Xian L:
Lentivirus-mediated gene therapy by suppressing survivin in BALB/c
nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther.
5:435–440. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pisarev V, Yu B, Salup R, Sherman S,
Altieri DC and Gabrilovich DI: Full-length dominant-negative
survivin for cancer immunotherapy. Clin Cancer Res. 9:6523–6533.
2003.PubMed/NCBI
|
|
10
|
Grossman D, Kim PJ, Schechner JS and
Altieri DC: Inhibition of melanoma tumor growth in vivo by survivin
targeting. Proc Natl Acad Sci USA. 98:635–640. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Verdecia MA, Huang H, Dutil E, Kaiser DA,
Hunter T and Noel JP: Structure of the human anti-apoptotic protein
survivin reveals a dimeric arrangement. Nat Struct Biol. 7:602–608.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Muchmore SW, Chen J, Jakob C, Zakula D,
Matayoshi ED, Wu W, Zhang H, Li F, Ng SC and Altieri DC: Crystal
structure and mutagenic analysis of the inhibitor-of-apoptosis
protein survivin. Mol Cell. 6:173–182. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
OConnor DS, Grossman D, Plescia J, Li F,
Zhang H, Villa A, Tognin S, Marchisio PC and Altieri DC: Regulation
of apoptosis at cell division by p34cdc2 phosphorylation of
survivin. Proc Natl Acad Sci USA. 97:13103–13107. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sanz MA, Grimwade D, Tallman MS, Lowenberg
B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Büchner T, Döhner H,
et al: Management of acute promyelocytic leukemia: Recommendations
from an expert panel on behalf of the European LeukemiaNet. Blood.
113:1875–1891. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Momeny M, Zakidizaji M, Ghasemi R, Dehpour
AR, Rahimi-Balaei M, Abdolazimi Y, Ghavamzadeh A, Alimoghaddam K
and Ghaffari SH: Arsenic trioxide induces apoptosis in NB-4, an
acute promyelocytic leukemia cell line, through up-regulation of
p73 via suppression of nuclear factor kappa B-mediated inhibition
of p73 transcription and prevention of NF-kappaB-mediated induction
of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 27:833–842. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ghaffari SH, Bashash D, Dizaji MZ,
Ghavamzadeh A and Alimoghaddam K: Alteration in miRNA gene
expression pattern in acute promyelocytic leukemia cell induced by
arsenic trioxide: a possible mechanism to explain arsenic
multi-target action. Tumour Biol. 33:157–172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gazitt Y and Akay C: Arsenic trioxide: An
anticancer missile with multiple warheads. Hematology. 10:205–213.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Seol JG, Park WH, Kim ES, Jung CW, Hyun
JM, Kim BK and Lee YY: Effect of arsenic trioxide on cell cycle
arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res
Commun. 265:400–404. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dizaji MZ, Malehmir M, Ghavamzadeh A,
Alimoghaddam K and Ghaffari SH: Synergistic effects of arsenic
trioxide and silibinin on apoptosis and invasion in human
glioblastoma U87MG cell line. Neurochem Res. 37:370–380. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL
and Yang CH: Arsenic trioxide in patients with hepatocellular
carcinoma: A phase II trial. Invest New Drugs. 25:77–84. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vuky J, Yu R, Schwartz L and Motzer RJ:
Phase II trial of arsenic trioxide in patients with metastatic
renal cell carcinoma. Invest New Drugs. 20:327–330. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim KB, Bedikian AY, Camacho LH,
Papadopoulos NE and McCullough C: A phase II trial of arsenic
trioxide in patients with metastatic melanoma. Cancer.
104:1687–1692. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kumar P, Gao Q, Ning Y, Wang Z, Krebsbach
PH and Polverini PJ: Arsenic trioxide enhances the therapeutic
efficacy of radiation treatment of oral squamous carcinoma while
protecting bone. Mol Cancer Ther. 7:2060–2069. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu YC, Yen WY, Lee TC and Yih LH: Heat
shock protein inhibitors, 17-DMAG and KNK437, enhance arsenic
trioxide-induced mitotic apoptosis. Toxicol Appl Pharmacol.
236:231–238. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang N, Wu ZM, McGowan E, Shi J, Hong ZB,
Ding CW, Xia P and Di W: Arsenic trioxide and cisplatin synergism
increase cytotoxicity in human ovarian cancer cells: Therapeutic
potential for ovarian cancer. Cancer Sci. 100:2459–2464. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li JX, Shen YQ, Cai BZ, Zhao J, Bai X, Lu
YJ and Li XQ: Arsenic trioxide induces the apoptosis in vascular
smooth muscle cells via increasing intracellular calcium and ROS
formation. Mol Biol Rep. 37:1569–1576. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Park MT, Kang YH, Park IC, Kim CH, Lee YS,
Chung HY and Lee SJ: Combination treatment with arsenic trioxide
and phytosphingosine enhances apoptotic cell death in arsenic
trioxide-resistant cancer cells. Mol Cancer Ther. 6:82–92. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jing Y, Dai J, Chalmers-Redman RM, Tatton
WG and Waxman S: Arsenic trioxide selectively induces acute
promyelocytic leukemia cell apoptosis via a hydrogen
peroxide-dependent pathway. Blood. 94:2102–2111. 1999.PubMed/NCBI
|
|
29
|
Li YM and Broome JD: Arsenic targets
tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res.
59:776–780. 1999.PubMed/NCBI
|
|
30
|
Yoo DR, Chong SA and Nam MJ: Proteome
profiling of arsenic trioxide-treated human hepatic cancer cells.
Cancer Genomics Proteomics. 6:269–274. 2009.PubMed/NCBI
|
|
31
|
Tirrò E, Consoli ML, Massimino M, Manzella
L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A,
et al: Altered expression of c-IAP1, survivin, and Smac contributes
to chemotherapy resistance in thyroid cancer cells. Cancer Res.
66:4263–4272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Konduri S, Colon J, Baker CH, Safe S,
Abbruzzese JL, Abudayyeh A, Basha MR and Abdelrahim M: Tolfenamic
acid enhances pancreatic cancer cell and tumor response to
radiation therapy by inhibiting survivin protein expression. Mol
Cancer Ther. 8:533–542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu JL, Zhang XJ, Zhang Z, Zhang AH, Wang
W and Dong JH: Meta-analysis: Prognostic value of survivin in
patients with hepatocellular carcinoma. PLoS One. 8:e833502013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Burdon RH: Control of cell proliferation
by reactive oxygen species. Biochem Soc Trans. 24:1028–1032. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Peng XC, Yang L, Yang LP, Mao YQ, Yang HS,
Liu JY, Zhang DM, Chen LJ and Wei YQ: Efficient inhibition of
murine breast cancer growth and metastasis by gene transferred
mouse survivin Thr34➝Ala mutant. J Exp Clin Cancer Res. 27:462008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li ZM, Zhao YW, Zhao CJ, Zhang XP, Chen
LJ, Wei YQ and Yang HS: Hyperthermia increases the therapeutic
efficacy of survivinT34A in mouse tumor models. Cancer Biol Ther.
12:523–530. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang AL, Wan Y, Liao DY, Hu HZ, Wei L,
Wang XH, Wen YJ, Li J, Chen LJ, Kan B, et al: Suppression of human
MDA-MB-435S tumor by U6 promoter-driven short hairpin RNAs
targeting focal adhesion kinase. J Cancer Res Clin Oncol.
136:1229–1242. 2010. View Article : Google Scholar : PubMed/NCBI
|
